Abstract 3541
Background
Cancer follow-up care continues to evolve to incorporate complex programs of supportive care to address long-term disease consequences. However, care may be prescriptive and fragmented, contributing to uncertainty among cancer survivors. As major stakeholders in follow-up care for cancer survivors, nurses are ideally positioned to ensure supportive care is person-centred and responsive to patients’ needs. We recently conducted a study to summarize the evidence related to cancer survivors’ preferences for supportive care and examine the ways in which these preferences are embedded in current guidelines and policies informing cancer survivorship care. This presentation discusses specific implications of these findings for oncology nursing.
Methods
Phase 1 of the study comprises an integrative review of the empirical literature regarding cancer survivors’ preferences for supportive care, with literature sourced from bibilographic databases and analysed according to principles of thematic analysis. In Phase 2, clinical practice guidelines and policy documents guiding supportive care in cancer survivorship are evaluated using content analysis methods to ascertain alignment with the findings of Phase 1. Finally, we conduct a critical analysis of the results through the lens of oncology nursing practice.
Results
Findings of the integrative review and content analysis of practice and policy guidelines highlight issues related to where and when supportive care is accessed and the types and features of supportive care services. Given that these gaps intersect with nursing practice, they serve as potential targets of knowledge translation activities. Impacts on survivors’ experiences are illustrated with exemplars derived from recent qualitative studies conducted in Canadian and Irish contexts.
Conclusions
As novel programs are developed to meet the needs of the growing population of cancer survivors, a consideration of survivors’ preferences is essential. We offer specific ways in which nursing practice and scholarship can be leveraged to ensure the translation of this knowledge into care, making visible the survivors’ voice in this process.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract